MBX Biosciences MBX Insider Ownership

Updated Oct 29, 2026

Over the past year, MBX insiders bought $525,663 of stock (18.5K shares) and sold $2.73 million (71.21K shares) on the open market.

• A count shows one insider buying MBX stock on the open market over the past 12 months and 2 insiders selling.
• Among MBX Biosciences insiders, P. Kent Hawryluk (President & CEO) led open-market buying over the past 12 months with $525,663 of purchases (18.5K shares); the latest was on March 13, 2026.
• On the selling side, Salomon Azoulay (Chief Medical Officer) sold the most MBX Biosciences stock on the open market over the past 12 months, $2.72 million (70.6K shares), most recently on August 4, 2026.
• In transactions other than open-market trades, MBX Biosciences insiders received 161.19K shares in stock awards and acquired 98.77K shares through option exercises and conversions over the past 12 months.
• According to Business Quant data, insiders at MBX Biosciences reported 13.87Mn shares in total in their latest Form 4 filings, or 28.93% of the 47.95Mn shares outstanding.
• By type of ownership, MBX insiders hold 7.17% of their shares directly (994.41K shares) and 92.83% indirectly (12.88Mn shares).
• Business Quant counts 12 insiders with holdings in MBX Biosciences stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• MBX's largest insider holders by reported holdings are Patrick J. Heron (Director and 10% owner, 5.22Mn shares), Edward T. Mathers (Director and 10% owner, 3.61Mn shares) and Tiba Aynechi (Director, 2.14Mn shares).
• Patrick J. Heron alone accounts for 37.62% of the shares held by MBX Biosciences insiders.
• A total of 23 Form 4 filings with transactions in MBX Biosciences stock were made over the past 12 months, by 12 insiders.
• These insider figures for MBX Biosciences are based on Form 4 filings through October 22, 2026.